Cambridge Cancer Genomics
Nirmesh Patel is the Chief Scientific Officer of Cambridge Cancer Genomics, a smart genomics company using liquid biopsies to better guide cancer therapy choice and offer truly personalised medicine.
Trained as a biomedical scientist at King’s College London, he has 10 years of experience in oncology research and a PhD in Translational Cancer Medicine where he used data science and bioinformatics to identify novel targets in breast cancer and biomarkers to predict patient response, launching multiple drug discovery efforts in collaboration with pharma.
He has always sat at the interface between laboratory research, data science and the clinic and is unifying the three fields with a mission to improve cancer patient treatment.
Monitoring cancer evolution through smart genomics and liquid biopsies
One of the major advantages of liquid biopsies is the ability to probe the same patient multiple times with low invasiveness. Thus, allowing us to monitor the evolution of the tumour and identify markers that indicate response and resistance to therapy. Here we show how the analysis of the chronological mutational landscape of tumours can offer new therapeutic approaches for limiting tumour recurrence.
EVEN MORE SEMINARS
Gareth Thomas BDS, MScD, PhD, FDSRCS, FRCPath University Hospital Southampton NHS Foundation Trust.
Targeted therapies: aiming at the tumour micro-environment
Michael Schreiber Brain Tumor Foundation, Chairman
Brain Tumors - Innovation, support and advocacy
Professor A. Graham Pockley multimmune GmbH / Nottingham Trent University
A new era of cancer therapeutics?
Mr Naga Venkatesh Jayanthi MD, FRCS Bupa - Consultant Surgeon
Minimal Invasive Oesophagectomy – where are we going?
Sanjay P Prabhu Boston Children’s Hospital & Harvard Medical School
Evolving role of machine learning in brain tumour imaging